Justin Lichter1,2,3, Eugene G Kholmovski4,5, Nicolas Coulombe6, Elyar Ghafoori1,2,3, Roya Kamali1,2,3, Rob MacLeod1,2,3, Ravi Ranjan1,2,3. 1. Division of Cardiovascular Medicine, University of Utah, 30 N 1900 E Rm 4A100, Salt Lake City, UT, USA. 2. Department of Bioengineering, University of Utah, Salt Lake City, UT, USA. 3. Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, USA. 4. UCAIR, Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT, USA. 5. CARMA Center, University of Utah, Salt Lake City, UT, USA. 6. Medtronic Cryopath LP, 9000 Trans-Canada Hwy, Pointe-Claire, Quebec, Canada.
Abstract
AIMS: The goals of this study were to develop a method that combines cryoablation with real-time magnetic resonance imaging (MRI) guidance for pulmonary vein isolation (PVI) and to further quantify the lesion formation by imaging both acute and chronic cryolesions. METHODS AND RESULTS: Investigational MRI-compatible cryoablation devices were created by modifying cryoballoons and cryocatheters. These devices were used in canines (n = 8) and a complete series of lesions (PVI: n = 5, superior vena cava: n = 4, focal: n = 13) were made under real-time MRI guidance. Late gadolinium enhancement (LGE) magnetic resonance imaging was acquired at acute and chronic time points. Late gadolinium enhancement magnetic resonance imagings show a significant amount of acute tissue injury immediately following cryoablation which subsides over time. In the pulmonary veins, scar covered 100% of the perimeter of the ostium of the veins acutely, which subsided to 95.6 ± 4.3% after 3 months. Focal point lesions showed significantly larger acute enhancement volumes compared to the volumes estimated from gross pathology measurements (0.4392 ± 0.28 cm3 vs. 0.1657 ± 0.08 cm3, P = 0.0043). Additionally, our results with focal point ablations indicate that freeze-zone formation reached a maximum area after 120 s. CONCLUSION: This study reports on the development of an MRI-based cryoablation system and shows that with acute cryolesions there is a large area of reversible injury. Real-time MRI provides the ability to visualize the freeze-zone formation during the freeze cycle and for focal lesions reaches a maximum after 120 s suggesting that for maximizing lesion size 120 s might be the lower limit for dosing duration.
AIMS: The goals of this study were to develop a method that combines cryoablation with real-time magnetic resonance imaging (MRI) guidance for pulmonary vein isolation (PVI) and to further quantify the lesion formation by imaging both acute and chronic cryolesions. METHODS AND RESULTS: Investigational MRI-compatible cryoablation devices were created by modifying cryoballoons and cryocatheters. These devices were used in canines (n = 8) and a complete series of lesions (PVI: n = 5, superior vena cava: n = 4, focal: n = 13) were made under real-time MRI guidance. Late gadolinium enhancement (LGE) magnetic resonance imaging was acquired at acute and chronic time points. Late gadolinium enhancement magnetic resonance imagings show a significant amount of acute tissue injury immediately following cryoablation which subsides over time. In the pulmonary veins, scar covered 100% of the perimeter of the ostium of the veins acutely, which subsided to 95.6 ± 4.3% after 3 months. Focal point lesions showed significantly larger acute enhancement volumes compared to the volumes estimated from gross pathology measurements (0.4392 ± 0.28 cm3 vs. 0.1657 ± 0.08 cm3, P = 0.0043). Additionally, our results with focal point ablations indicate that freeze-zone formation reached a maximum area after 120 s. CONCLUSION: This study reports on the development of an MRI-based cryoablation system and shows that with acute cryolesions there is a large area of reversible injury. Real-time MRI provides the ability to visualize the freeze-zone formation during the freeze cycle and for focal lesions reaches a maximum after 120 s suggesting that for maximizing lesion size 120 s might be the lower limit for dosing duration.
Authors: Jason G Andrade; Marc Dubuc; Peter G Guerra; Evelyn Landry; Nicolas Coulombe; Hugues Leduc; Léna Rivard; Laurent Macle; Bernard Thibault; Mario Talajic; Denis Roy; Paul Khairy Journal: J Cardiovasc Electrophysiol Date: 2013-03-13
Authors: Sheldon M Singh; Andre d'Avila; Steve K Singh; Paul Stelzer; Eduardo B Saad; Allan Skanes; Arash Aryana; Jason S Chinitz; Robert Kulina; Marc A Miller; Vivek Y Reddy Journal: Heart Rhythm Date: 2013-08-13 Impact factor: 6.343
Authors: Justin Ghosh; Andrew Martin; Anthony C Keech; Kim H Chan; Sean Gomes; Suresh Singarayar; Mark A McGuire Journal: Heart Rhythm Date: 2013-06-19 Impact factor: 6.343
Authors: Ravi Ranjan; Eugene G Kholmovski; Joshua Blauer; Sathya Vijayakumar; Nelly A Volland; Mohamed E Salama; Dennis L Parker; Rob MacLeod; Nassir F Marrouche Journal: Circ Arrhythm Electrophysiol Date: 2012-10-15
Authors: Saman Nazarian; Aravindan Kolandaivelu; Menekhem M Zviman; Glenn R Meininger; Ritsushi Kato; Robert C Susil; Ariel Roguin; Timm L Dickfeld; Hiroshi Ashikaga; Hugh Calkins; Ronald D Berger; David A Bluemke; Albert C Lardo; Henry R Halperin Journal: Circulation Date: 2008-06-23 Impact factor: 29.690
Authors: Ehud J Schmidt; Richard P Mallozzi; Aravinda Thiagalingam; Godtfred Holmvang; Andre d'Avila; Renee Guhde; Robert Darrow; Glenn S Slavin; Maggie M Fung; Jeremy Dando; Lori Foley; Charles L Dumoulin; Vivek Y Reddy Journal: Circ Arrhythm Electrophysiol Date: 2009-12
Authors: Kamran Ahrar; Judy U Ahrar; Sanaz Javadi; Li Pan; Denái R Milton; Christopher G Wood; Surena F Matin; R Jason Stafford Journal: Invest Radiol Date: 2013-06 Impact factor: 6.016
Authors: Xinzhou Li; Luigi E Perotti; Jessica A Martinez; Sandra M Duarte-Vogel; Daniel B Ennis; Holden H Wu Journal: PLoS One Date: 2020-02-26 Impact factor: 3.240
Authors: Sophie C Rier; Suzan Vreemann; Wouter H Nijhof; Vincent J H M van Driel; Ivo A C van der Bilt Journal: Ther Adv Cardiovasc Dis Date: 2022 Jan-Dec